Research Comparison
Adipotide (Prohibitin-TP01) vs Semaglutide
A side-by-side research comparison of Adipotide (Prohibitin-TP01) and Semaglutide drawn from Cobalt Peptides' peptide database records.
Adipotide (Prohibitin-TP01)
Adipotide (Prohibitin-TP01) is a chimeric peptidomimetic combining a targeting sequence (CKGGRAKDC) that binds prohibitin and annexin A2 on adipose endothelial cells with a pro-apoptotic mitochondrial-disrupting motif, D-(KLAKLAK)2. It was investigated in preclinical models of adiposity. Its development was HALTED following early clinical investigation because of renal safety findings — reversible proximal tubule toxicity observed in primate studies. It is not an approved medicine and is supplied strictly as a research compound for laboratory use.
Semaglutide
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It is acylated with a C18 fatty diacid through a γ-glutamyl spacer, which promotes albumin binding and extends its half-life to approximately seven days. The published literature describes GLP-1 receptor activation with downstream effects on insulin secretion, glucagon suppression and gastric emptying. Licensed medicines containing semaglutide exist and are prescribed by clinicians; the material supplied here is a research compound and is not one of them.